Ocular problems are common in patients with ANCA-associated vasculitis (AAV), affecting 23.1% of all patients with the disease[5]. Among the three types of AAV, granulomatosis with polyangiitis (GPA) is most associated with ocular complications, affecting 30.3% of patients with GPA, while only 4.2% of patients with microscopic polyangiitis (MPA) and 3.5% of patients with eosinophilic granulomatosis with polyangiitis (EGPA)[3]. The most common ocular manifestations are conjunctivitis, scleritis, and corneal inflammation, with cataract being the most common complication, occurring in 9.1–15.3% of patients[3]. Retinal involvement, including inflammatory processes and vascular occlusion, occurs mainly in patients with EGPA[1]. Patients with ocular complications of AAV have a 2.75 times higher mortality rate compared to other patients with ocular inflammation, despite the use of corticosteroids and immunosuppressive drugs[2]. New ocular manifestations rarely occur after the onset of the disease, suggesting that most ocular problems appear in the early stages of the disease[3].